Where to buy Pimitespib

Pimitespib, an oral heat shock protein (HSP) 90 inhibitor Jeselhy tablet 40 mg, is indicated for gastrointestinal stromal tumor (GIST) that has progressed after chemotherapy. The compound pimetibi, discovered by Dabao Pharmaceutical, inhibits HSP90, thereby showing anti-tumor effects by destroying and reducing proteins related to cancer growth and survival, such as KIT, PDGFRA, HER2 and EGFR.

The approval is based on results from a Phase III trial comparing the efficacy and safety of pimoteb with placebo in patients with previously treated gastrointestinal stromal tumors. In the trial, pimetibib extended the primary endpoint of progression-free survival (PFS) and demonstrated that adverse events were manageable. Cells are constantly exposed to various stresses in the body. Cancer cells in particular are exposed to a great deal of stress, manifested by hypoxia, malnutrition, clearance by the immune system, and genetic instability. The expression of pimetibib increases with stress, protecting cells from stress and promoting cell survival by maintaining the structural and functional integrity of the protein.

Pimetibi is overexpressed and exists in a highly active state in cancer cells and tumor tissues, and is known to be particularly important in the survival and maintenance of cancer. Additionally, the expression of pimetibib in gastrointestinal stromal tumors, bladder cancer, acute myeloid leukemia, breast cancer, non-small cell lung cancer, colorectal cancer, and melanoma has been reported to be associated with cancer progression and/or patient prognosis.

Pimetibi is not marketed in China, and it has been on the market overseas for a short time, and there is little information about its price and other related information. For more drug information and specific prices, please consult Yaode Medical Consultant.